Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Monica Verdoia; Patrizia Pergolini; Roberta ROLLA; Matteo Nardin; Lucia Barbieri; Veronica Daffara; Paolo MARINO; Giorgio BELLOMO; Harry Suryapranata; GIUSEPPE DE LUCA

doi:10.1007/s10557-016-6646-5

Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Monica Verdoia
, Patrizia Pergolini
, Roberta ROLLA
, Matteo Nardin
, Lucia Barbieri
, Veronica Daffara
, Paolo MARINO
, Giorgio BELLOMO
, Harry Suryapranata
, GIUSEPPE DE LUCA

Department of Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

Original language	English
Pages (from-to)	143-150
Number of pages	8
Journal	Cardiovascular Drugs and Therapy
Volume	30
Issue number	2
DOIs	https://doi.org/10.1007/s10557-016-6646-5
Publication status	Published - 2016

Keywords

Clopidogrel
Coronary artery disease
Dual antiplatelet therapy
Gender
Platelet aggregation
Ticagrelor

Access to Document

10.1007/s10557-016-6646-5

http://hdl.handle.net/11579/75750

Cite this

@article{38b9fb0cb3fd4b74a999c6f555bec1b2,

title = "Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy",

abstract = "Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.",

keywords = "Clopidogrel, Coronary artery disease, Dual antiplatelet therapy, Gender, Platelet aggregation, Ticagrelor, Clopidogrel, Coronary artery disease, Dual antiplatelet therapy, Gender, Platelet aggregation, Ticagrelor",

author = "Monica Verdoia and Patrizia Pergolini and Roberta ROLLA and Matteo Nardin and Lucia Barbieri and Veronica Daffara and Paolo MARINO and Giorgio BELLOMO and Harry Suryapranata and \{DE LUCA\}, GIUSEPPE",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

doi = "10.1007/s10557-016-6646-5",

language = "English",

volume = "30",

pages = "143--150",

journal = "Cardiovascular Drugs and Therapy",

issn = "1573-7241",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

AU - Verdoia, Monica

AU - Pergolini, Patrizia

AU - ROLLA, Roberta

AU - Nardin, Matteo

AU - Barbieri, Lucia

AU - Daffara, Veronica

AU - MARINO, Paolo

AU - BELLOMO, Giorgio

AU - Suryapranata, Harry

AU - DE LUCA, GIUSEPPE

PY - 2016

Y1 - 2016

N2 - Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

AB - Cardiovascular risk is still underestimated in women, experiencing higher mortality and worse prognosis after acute cardiovascular events. Gender differences have been reported in thrombotic and hemorrhagic risk during dual antiplatelet therapy (DAPT), thus suggesting a potential variability in platelet reactivity according to sex. The aim of the present study was to assess the role of gender on platelet function and the prevalence of high-on treatment residual platelet reactivity (HRPR) during DAPT in patients with recent acute coronary syndrome or percutaneous coronary revascularization.

KW - Clopidogrel

KW - Coronary artery disease

KW - Dual antiplatelet therapy

KW - Gender

KW - Platelet aggregation

KW - Ticagrelor

KW - Clopidogrel

KW - Coronary artery disease

KW - Dual antiplatelet therapy

KW - Gender

KW - Platelet aggregation

KW - Ticagrelor

UR - https://iris.uniupo.it/handle/11579/75750

U2 - 10.1007/s10557-016-6646-5

DO - 10.1007/s10557-016-6646-5

M3 - Article

SN - 1573-7241

VL - 30

SP - 143

EP - 150

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 2

ER -

Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this